ProMIS Neurosciences, Inc. Stock Toronto S.E.
Stocks
PMN
CA74346M4065
Biotechnology & Medical Research
| Market Cap | 184M 132M 114M 107M 97.57M 12.58B 187M 1.25B 491M 6.29B 495M 485M 20.96B | P/E 2026 * |
-3.04x | P/E 2027 * | -3.93x |
|---|---|---|---|---|---|
| Enterprise Value | 184M 132M 114M 107M 97.57M 12.58B 187M 1.25B 491M 6.29B 495M 485M 20.96B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
88.15% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -3.85% |
| Manager | Title | Age | Since |
|---|---|---|---|
Neil Warma
CEO | Chief Executive Officer | 63 | 2023-12-29 |
Neil Cashman
CTO | Chief Tech/Sci/R&D Officer | 74 | 2004-05-30 |
Daniel Geffken
DFI | Director of Finance/CFO | 69 | 2017-03-21 |
| Director | Title | Age | Since |
|---|---|---|---|
Neil Cashman
CHM | Chairman | 74 | 2012-10-02 |
William Wyman
CHM | Chairman | 88 | 2014-06-11 |
Eugene Williams
CHM | Chairman | 66 | 2015-06-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.85% | -21.05% | - | - | 132M | |
| +4.21% | +25.62% | +77.96% | +111.62% | 68.12B | |
| +0.50% | +6.20% | +38.65% | +67.83% | 55.18B | |
| +3.07% | +35.25% | +17.95% | +486.05% | 28.63B | |
| +0.57% | +19.05% | +57.08% | +5.18% | 23.99B | |
| -0.73% | +1.08% | -14.65% | -11.58% | 23.53B | |
| -0.35% | +7.91% | +46.74% | -22.61% | 18.45B | |
| -2.04% | +9.24% | +31.14% | +650.71% | 16.44B | |
| +7.26% | +25.47% | +221.03% | +383.67% | 15.83B | |
| -2.15% | -4.40% | +40.70% | +148.87% | 13.4B | |
| Average | +0.50% | +11.31% | +57.40% | +202.19% | 29.28B | |
| Weighted average by Cap. | +1.54% | +11.64% | +54.64% | +164.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -59.04M -42.36M -36.67M -34.28M -31.33M -4.04B -59.96M -402M -158M -2.02B -159M -156M -6.73B | -70.36M -50.49M -43.71M -40.85M -37.34M -4.82B -71.46M -479M -188M -2.41B -190M -185M -8.02B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
